Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Company Overview - Theravance Biopharma, Inc. focuses on delivering Medicines that Make a Difference® in people's lives [2] - The company has developed the FDA-approved YUPELRI® (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD) [2] - Ampreloxetine, a late-stage investigational drug, is being developed for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA) and has the potential to be a first-in-class therapy [2] Upcoming Events - Theravance Biopharma's management team will hold investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco, CA [1]